Crinetics Pharmaceuticals Inc (CRNX)

$54.36

+1.02

(+1.91%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $53.36
    $54.93
    $54.36
    downward going graph

    1.84%

    Downside

    Day's Volatility :2.86%

    Upside

    1.04%

    downward going graph
  • $15.76
    $55.78
    $54.36
    downward going graph

    71.01%

    Downside

    52 Weeks Volatility :71.75%

    Upside

    2.55%

    downward going graph

Returns

PeriodCrinetics Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
26.64%
6.5%
0.0%
6 Months
43.46%
7.1%
0.0%
1 Year
182.82%
9.8%
0.0%
3 Years
190.05%
14.2%
-20.2%

Highlights

Market Capitalization
4.2B
Book Value
$11.14
Earnings Per Share (EPS)
-3.77
Wall Street Target Price
69.08
Profit Margin
0.0%
Operating Margin TTM
-11488.91%
Return On Assets TTM
-24.01%
Return On Equity TTM
-40.76%
Revenue TTM
2.0M
Revenue Per Share TTM
0.03
Quarterly Revenue Growth YOY
-76.1%
Gross Profit TTM
-125.5M
EBITDA
-246.9M
Diluted Eps TTM
-3.77
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.57
EPS Estimate Next Year
-3.81
EPS Estimate Current Quarter
-0.81
EPS Estimate Next Quarter
-0.8

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Crinetics Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
17
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 27.08%

Current $54.36
Target $69.08

Technicals Summary

Sell

Neutral

Buy

Crinetics Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
26.43%
43.46%
182.82%
190.05%
142.12%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
NA
NA
NA
-3.57
-0.41
-0.24
NA
11.14
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
Buy
$4.2B
142.12%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Crinetics Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 346.0K → 640.0K (in $), with an average increase of 45.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 7 quarters, -40.39M → -66.93M (in $), with an average decrease of 8.9% per quarter

Institutional Holdings

  • BlackRock Inc

    6.89%

  • Driehaus Capital Management LLC

    6.63%

  • Point72 Asset Management, L.P.

    6.28%

  • FMR Inc

    5.66%

  • EcoR1 Capital, LLC

    5.27%

  • T. Rowe Price Associates, Inc.

    4.85%

Corporate Announcements

  • Crinetics Pharmaceuticals Inc Earnings

    Crinetics Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.

Organization
Crinetics Pharmaceuticals Inc
Employees
290
CEO
Dr. R. Scott Struthers Ph.D.
Industry
Health Technology

Discover More

FAQs